Kymera Therapeutics, Inc.

KYMR

US5015751044

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 03:50:46 2024-04-24 pm EDT			5-day change	1st Jan Change
35.22 ^USD	-1.37%		+4.65%	+38.77%

Apr. 22	Oppenheimer Starts Kymera Therapeutics With Outperform Rating, $53 Price Target	MT
Apr. 08	Kymera Therapeutics, Inc Announces Scientific Presentations At the American Association for Cancer Research 2024 Annual Meeting	CI

Kymera Therapeutics, Inc. Announces Departure of Richard Chesworth from Chief Scientific Officer, Effective October 22, 2021

September 16, 2021 at 04:02 pm EDT

On September 16th, 2021, Kymera Therapeutics, Inc. announced that Richard Chesworth, its Chief Scientific Officer, will be departing the Company effective as of October 22, 2021.

Latest news about Kymera Therapeutics, Inc.

Oppenheimer Starts Kymera Therapeutics With Outperform Rating, $53 Price Target	Apr. 22	MT
Kymera Therapeutics, Inc Announces Scientific Presentations At the American Association for Cancer Research 2024 Annual Meeting	Apr. 08	CI
Kymera Therapeutics, Inc. Appoints Felix J. Baker to the Board	Apr. 01	CI
Kymera Therapeutics Insider Sold Shares Worth $14,912,376, According to a Recent SEC Filing	Mar. 14	MT
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs At the American Academy of Dermatology Annual Meeting	Mar. 08	CI
Truist Ups Price Target on Kymera Therapeutics to $54 From $41, Keeps Buy Rating	Mar. 01	MT
Piper Sandler Raises Price Target on Kymera Therapeutics to $56 From $39, Maintains Overweight Rating	Feb. 27	MT
B. Riley Adjusts Kymera Therapeutics' Price Target to $31 From $16, Keeps Neutral Rating	Feb. 23	MT
Kymera Therapeutics Q4 Net Loss Narrows, Collaboration Revenue Rises	Feb. 22	MT
Transcript : Kymera Therapeutics, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Kymera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Kymera Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Wolfe Research Starts Kymera Therapeutics With Peer Perform Rating	Feb. 15	MT
Kymera Therapeutics Insider Sold Shares Worth $300,470, According to a Recent SEC Filing	Jan. 24	MT
Transcript : Kymera Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:00 AM	Jan. 09
Kymera Therapeutics Raises $316.2 Million From Offering, Outlines Cash Runway Guidance	Jan. 09	MT
Morgan Stanley Raises Price Target on Kymera Therapeutics to $33 From $24, Keeps Equalweight Rating	Jan. 08	MT
Kymera Therapeutics Prices $275 Million Common Share Public Offering	Jan. 05	MT
Kymera Therapeutics Launches $250 Million Public Share Offering	Jan. 05	MT
Transcript : Kymera Therapeutics, Inc. - Special Call	Jan. 04
Kymera Therapeutics, Inc. Intends to Initiate A Phase 1 Clinical Trial in the Second Half of 2024 and Report the Phase 1 Results in 2025	Jan. 04	CI
North American Morning Briefing : S&P 500 Futures -2-	Jan. 04	DJ
Kymera Therapeutics Shares Decline on BofA Securities Downgrade	Jan. 03	MT
BofA Securities Downgrades Kymera Therapeutics to Neutral From Buy, Price Target is $30	Jan. 03	MT
North American Morning Briefing : S&P 500 Futures -2-	Dec. 20	DJ

Chart Kymera Therapeutics, Inc.

Duration

Period

More charts

Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the bodyâs own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. It utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platformâs capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Kymera Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

35.71 USD

Average target price

51.07 USD

Spread / Average Target

+43.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
KYMERA THERAPEUTICS, INC.	+38.77%	2.18B
IQVIA HOLDINGS INC.	+3.98%	43.43B
LONZA GROUP AG	+47.81%	41.69B
MODERNA, INC.	+9.66%	41.31B
CELLTRION, INC.	-10.92%	27.14B
ICON PUBLIC LIMITED COMPANY	+9.27%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-24.85%	18.47B
MEDPACE HOLDINGS, INC.	+29.63%	12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.95%	12.33B
UNITED THERAPEUTICS CORPORATION	+8.22%	11.03B

Other Biotechnology & Medical Research